SCHEMBL18878383

SCHEMBL18878383

Cc1cc(CC(C)C)ccc1C(=O)C(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 1/20 0.47
GABRB2 P47870 1/20 0.47
PTGS1 P23219 4/20 0.42
PTGS2 P35354 4/20 0.42
LMNA P02545 2/20 0.42
CYP2C9 P11712 2/20 0.42
AKR1C3 P42330 2/20 0.42
CXCR1 P25024 2/20 0.42
CXCR2 P25025 2/20 0.42
AKR1C2 P52895 2/20 0.42
ALOX5 P09917 2/20 0.42
ALB P02768 1/20 0.42
ESR1 P03372 1/20 0.42
RARB P10826 1/20 0.42
ADRB3 P13945 1/20 0.42
NFKB1 P19838 1/20 0.42
HTR2A P28223 1/20 0.42
NR1I3 Q14994 1/20 0.42
SLC22A6 Q4U2R8 1/20 0.42
CXCL8 P10145 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10159905 0.84 AKR1C2 (0.49) GABRA1GABRB2PTGS1PTGS2LMNA
SCHEMBL17749108 0.81 GABRA1 (0.42) GABRA1GABRB2PTGS1PTGS2LMNA
SCHEMBL2238065 0.78 RXRA (0.47) GABRA1GABRB2PTGS1PTGS2LMNA
SCHEMBL29394461 0.78 RXRA (0.47) GABRA1GABRB2PTGS1PTGS2LMNA
SCHEMBL2237603 0.77 EPHX1 (0.46) GABRA1GABRB2PTGS1PTGS2LMNA
SCHEMBL27864666 0.77 GABRA1 (0.45) GABRA1GABRB2PTGS1PTGS2LMNA
SCHEMBL18878384 0.77 FFAR1 (0.42) GABRA1GABRB2PTGS1PTGS2LMNA
SCHEMBL3675412 0.76 PTGS1 (0.53) PTGS1PTGS2LMNACYP2C9AKR1C3
SCHEMBL5716706 0.76 TAS1R3 (0.46) LMNA
SCHEMBL18878382 0.75 NPSR1 (0.37) GABRA1GABRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9951074-B2 Dihydropteridinone derivatives and uses thereof DANA-FARBER CANCER INSTITUTE, INC. (US) 2018-04-24 US disclosed
US-20170145013-A1 DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2017-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170145013-A1 DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF BRDT, BRD4, BRD3 GABRA1 2843/4885GABRB2 1247/4885PTGS1 987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.